News

Image source: The Motley Fool.

AstraZeneca Plc (NASDAQ: AZN)Q3 2023 Earnings CallNov 09, 2023, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Benjamin Franklin would probably be disappointed that the $100 bill that bears his likeness isn't worth what it used to be. However, there are actually plenty of great stocks to be found that you

Shares of Conduit Pharmaceuticals (NASDAQ: CDT) were up more than 17% on Wednesday as of 11:30 a.m., after jumping up as much as 81% in the first hour of trading, leading to a brief halt in trading

Growth: It's what every investor would like to have from the stocks they buy. That's true even for individuals who are primarily seeking income.

Three Fool.com contributors believe they've

On average, healthcare stocks haven't kept up with the gains made by the rest of the market this year. While the S&P 500 index is up by more than 17% year to date, that sector's stocks are down by

If you've invested in biopharma anytime recently, you've probably heard the acronym NASH. It stands for nonalcoholic steatohepatitis, a liver disease characterized by fat accumulating on the liver

Fool.com contributor Parkev Tatevosian evaluates GSK (NYSE: GSK) and its longer-term prospects to determine if it's a fantastic stock to buy for dividend stock investors.

*Stock prices used were

The right companies can help investors improve their personal balance sheets. That is because businesses that reliably grow sales and earnings become more valuable to financial markets with each

GSK (NYSE: GSK), a global healthcare company, initiated the separation of its consumer healthcare business, Haleon, last year, as part of its ambitious restructuring plan that CEO Emma Walmsley

Image source: The Motley Fool.

AstraZeneca Plc (NASDAQ: AZN)Q2 2023 Earnings CallJul 28, 2023, 6:45 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Vir Biotechnology (NASDAQ: VIR) were down more than 44% as of 10:45 a.m. on Thursday after the company announced phase 2 trial results for an influenza A therapy candidate. The stock is

Healthcare stocks, particularly pharmaceutical stocks with solid dividends, make great long-term investments.

In general, the need for healthcare products and services is stable, even during

Late last year, Open AI's ChatGPT introduced the wider world to the immense power of artificial intelligence (AI). However, pharmaceutical companies have been experimenting with various forms of

Dividend-paying pharmaceutical stocks have an outstanding track record of producing market-beating returns on capital. The core reason is that major drug manufacturers tend to generate enormous free

Sometimes, a company hits a stumbling block -- or several of them. The stock plummets, and investors lose faith. But, in some cases, these down-on-their luck companies are able to turn things

Shares of CureVac (NASDAQ: CVAC) were up by 14.3% for the week as of Friday morning, after having been up by as much as 16%, according to data provided by S&P Global Market Intelligence. The

Stock markets have performed well over the past few months, but Wall Street wasn't able to keep the upward momentum going this week. On Friday morning, major market benchmarks opened lower, with

Dividend-paying pharmaceutical stocks have a rich tradition of delivering market-beating returns on capital. An aging global population, the expansion of healthcare coverage under the Affordable

Not for the first time this year, Horizon Technology Finance (NASDAQ: HRZN) is tapping the public markets for a fresh round of capital-raising. Investors clearly didn't consider that to be good

With savvy stock-picking and a bit of patience, building wealth isn't as difficult as it is often made out to be. This is because quality businesses grow their revenue and profits, which makes their

First Horizon (NYSE: FHN) saw its stock price rise 13.7% this week, as of Friday's opening bell, according to S&P Global Market Intelligence. The stock had been up as much as 14.7% during the week

Shares of Horizon Therapeutics (NASDAQ: HZNP), a rare disease specialist, were down by 17.4% on heavy volume as of 10:14 a.m. ET Tuesday morning. The drugmaker's shares are falling after news broke

Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark. And smaller companies that lack any approved

Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been